Neurocrine Biosciences (NBIX) Total Debt Growth (1y) (2023)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Total Debt Growth (1y) (2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn | -2.50% |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn | -4.39% |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn | 52.27% |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn | 15.32% |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn | 2.26% |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn | 8.51% |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn | -17.14% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.59 Bn | 15.20 Bn | 935.80 Mn | - |